Loading
companiesCompany
SEngine Precision Medicine
Runs the PARIS test: a patient's tumour grown as organoids and screened against 240+ drugs to find options sequencing cannot see.
Overview
SEngine Precision Medicine, based in Seattle, runs the PARIS test, in which a patient's tumour is grown as organoids and screened against more than 240 drugs to find options that sequencing cannot see. It is CLIA-certified in all fifty states and approved by New York's CLEP, PARIS uses three-dimensional organoids from any solid tumour to rank drug sensitivity, it collaborates with Dana-Farber and Gustave Roussy, and it has raised about 19 million dollars through its Series A. OnCo links it to functional ex vivo drug testing and patient-derived organoids, to the bottleneck of preclinical models that do not predict people, and to the idea of holding organoid tests to the standard of a diagnostic. Whether organoid drug sensitivity predicts patient response well enough to guide therapy is the open question. The organoid technology page carries the evidence.
Similar pages
- CompanyXilis
Shares Hold organoid drug tests to the same standard as a diagnostic test, Organoid-guided therapy at scale, Grow each trial patient's tumour as organoids to decide which platform arm opens next, Test drugs on the patient's own cancer cells when there is no trial to join.
- CompanyCuresponse
Shares Hold organoid drug tests to the same standard as a diagnostic test, Organoid-guided therapy at scale, Grow each trial patient's tumour as organoids to decide which platform arm opens next, Test drugs on the patient's own cancer cells when there is no trial to join.
- TechnologyPDAC organoid pharmacotyping
Shares Organoid-guided therapy at scale, Grow each trial patient's tumour as organoids to decide which platform arm opens next, Functional (ex vivo) drug testing, Drug discovery roadmap: screening in mice → maps of dependency → designing in silico.
- CompanyChampions Oncology
Shares Test drugs on the patient's own cancer cells when there is no trial to join, Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, Patient-derived organoids, Lab models that fail to predict what happens in patients.
- IdeaA bone marrow niche on a chip to study human dormancy
Shares Functional (ex vivo) drug testing, Patient-derived organoids, Lab models that fail to predict what happens in patients.
- IdeaPatient-derived organoids to pick ADC payloads
Shares Grow each trial patient's tumour as organoids to decide which platform arm opens next, Functional (ex vivo) drug testing, Patient-derived organoids, Lab models that fail to predict what happens in patients.
- IdeaTest drugs on freshly cut slices of the patient's own tumour
Shares Functional (ex vivo) drug testing, Patient-derived organoids, Lab models that fail to predict what happens in patients.
- IdeaLinked human organ chips to predict side effects before people are dosed
Shares Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, Patient-derived organoids, Lab models that fail to predict what happens in patients.